Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Journal of hepatology - 1 Jul 2013

Silva Marcelo O, Treitel Michelle, Graham Donald J, Curry Stephanie, Frontera Maria J, McMonagle Patricia, Gupta Samir, Hughes Eric, Chase Robert, Lahser Fred, Barnard Richard J O, Howe Anita Y M, Howe John A

Abstract excerpt

BACKGROUND & AIMS: To examine the antiviral activity of boceprevir, a hepatitis C virus (HCV) protease inhibitor, in HCV genotype (G) 2/3-infected patients. METHODS: We assessed boceprevir and telaprevir activity against an HCV G2 and G3 isolates enzyme panel, in replicon, and in phenotypic cell-based assays. Additionally, a phase I study evaluated the antiviral activity of boceprevir monotherapy (200mg BID,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to Replicon

Share to Viral Load

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 23454058
DOI: 10.1016/j.jhep.2013.02.018

Genes

BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.PMID 23454058Read ↗

Boceprevir: a protease inhibitor for the treatment of hepatitis C.Semantic proximity Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.Semantic proximity Read ↗

Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.Semantic proximity Read ↗

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Semantic proximity Read ↗

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.Semantic proximity Read ↗

Boceprevir for previously treated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.Semantic proximity Read ↗

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.